Patient-reported outcomes from ENGOT-ov65/KEYNOTE-B96: a phase 3, randomized, double-blind study of pembrolizumab vs placebo plus paclitaxel with or without bevacizumab for platinum-resistant recurrent ovarian cancer

International Journal of Gynecological Cancer 2026

View at publisher
Authors: Emese Zsíros, Rutie Yin, Lucy Gilbert, Radosław Mądry, Pablo Rodriguez Monarca, Ram Eitan, Mayu Yunokawa, Fatih Köse, Yamil Alonso Lopez Chuken, John McGrane, Andrew Dean, Nelleke P.B. Ottevanger
+9 more Andrea Juliana Gomes, Thaïs Baert, Eun Ji Nam, Agata M. Bogusz, Allison Martin Nguyen, Helen Ding, Thomas Jemielita, Laura Deiana, Nicoletta Colombo
DOI: 10.1016/j.ijgc.2026.104568
Cited by: 0

Fields of Study & Subjects

Ovarian cancer diagnosis and treatment PARP inhibition in cancer therapy Endometrial and Cervical Cancer Treatments

Publication details

Journal / source
International Journal of Gynecological Cancer
Volume
36
Issue
2
Pages
104568–104568
Publication date
1 February 2026
Language
EN